Silco Pharmaceuticals Cash Flow Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Net Income	45.88	69.22	84.45	84.65	83.18
Depreciation & Amortization	93.22	90.53	78.49	78.4	78.69
Loss (Gain) From Sale of Investments	0.72	-18.56	-6.48	-0.42	-
Other Operating Activities	7.67	13.22	16.77	-9.2	22.4
Change in Accounts Receivable	-42.09	11.73	1.3	94.46	5
Change in Inventory	0.05	13.7	-8.39	5.26	-28.68
Change in Accounts Payable	-0.15	-2.58	-3.82	-2.7	0.68
Change in Other Net Operating Assets	-20.98	3.22	6.76	6.77	-14.65
Operating Cash Flow	84.31	180.48	169.08	257.21	146.61
Operating Cash Flow Growth	-53.29%	6.74%	-34.26%	75.44%	81.52%
Capital Expenditures	-84.26	-181.95	-106.13	-376.43	-170.05
Investment in Securities	22.96	22.71	-28.81	136.17	-5.95
Other Investing Activities	-0.72	18.56	6.48	0.42	0
Investing Cash Flow	-62.01	-140.68	-128.47	-239.83	-176.01
Long-Term Debt Repaid	-4.3	-4.11	-3.77	-3.54	-
Net Debt Issued (Repaid)	-4.3	-4.11	-3.77	-3.54	-
Common Dividends Paid	-19.14	-31.45	-62.62	-62.01	-18.39
Other Financing Activities	-0.93	-0.2	-0.53	-0.76	-1.96
Financing Cash Flow	-24.37	-35.76	-66.93	-66.31	-20.35
Miscellaneous Cash Flow Adjustments	-	0	-0	0	-
Net Cash Flow	-2.06	4.05	-26.31	-48.94	-49.75
Free Cash Flow	0.05	-1.47	62.95	-119.22	-23.45
Free Cash Flow Margin	0.01%	-0.32%	11.25%	-19.84%	-3.20%
Free Cash Flow Per Share	0.00	-0.01	0.61	-1.15	-0.23
Cash Interest Paid	0.93	0.2	0.53	0.76	-
Cash Income Tax Paid	6.73	6.99	8.27	14.95	5.32
Levered Free Cash Flow	-13.19	-11.75	36.24	-142.51	-52.35
Unlevered Free Cash Flow	-12.54	-11.55	36.57	-142.03	-52.35
Change in Working Capital	-63.17	26.07	-4.15	103.78	-37.66

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.